狼疮肾炎中起始中剂量与高剂量泼尼松的12个月肾脏缓解率相当
该多中心队列研究纳入162例新发活检证实的狼疮肾炎患者,比较起始高剂量(>40 mg/天)与低中剂量(≤40 mg/天)泼尼松的12个月完全肾脏缓解率。结果显示两组12个月完全肾脏缓解率无显著差异(低中剂量组65.4% vs 高剂量组71.2%,P=0.55),高剂量组第一年累积泼尼松暴露量显著更高(6.9 g vs 4.0 g,P<0.001)。多变量回归及时间-缓解分析均未显示高起始剂量与更好的肾脏缓解相关。
要点
- 高剂量与低中剂量起始泼尼松的12个月完全肾脏缓解率无显著差异。
- 高剂量组第一年累积泼尼松暴露量显著更高,但第2、3年累积剂量趋于相等。
- 多变量回归中较高初始泼尼松剂量与完全肾脏缓解率无关(调整OR 1.00)。
核心结论
- 在当代狼疮肾炎队列中,尽管显著增加糖皮质激素暴露,较高的起始泼尼松剂量与12个月肾脏缓解率改善无关。
研究设计与样本
- 回顾性和前瞻性队列研究,纳入2014年至今新发活检证实的狼疮肾炎患者,共162例。
主要发现
- 低中剂量组(≤40 mg/天,中位30 mg/天)101例,高剂量组(>40 mg/天,中位60 mg/天)61例。
- 12个月完全肾脏缓解率:低中剂量组65.4% vs 高剂量组71.2%(P=0.55)。
- 第一年累积泼尼松暴露量:高剂量组6.9 g vs 低中剂量组4.0 g(P<0.001),第2、3年累积剂量趋于相等。
- 多变量 logistic 回归联合 IPTW:较高初始泼尼松剂量与完全肾脏缓解率无关(调整OR 1.00;95%CI 0.46-2.22)。
- 时间-缓解分析显示总肾脏缓解无差异(log-rank P=0.26)。
关键数值与推荐
- 完全肾脏缓解率:低中剂量组65.4% vs 高剂量组71.2%(P=0.55)。
- 调整OR 1.00(95%CI 0.46-2.22)。
- 第一年累积泼尼松剂量:高剂量组6.9 g vs 低中剂量组4.0 g(P<0.001)。
临床怎么用
- 在狼疮肾炎患者中,较高起始泼尼松剂量并未显示改善12个月肾脏缓解率,但显著增加第一年累积糖皮质激素暴露。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The optimal starting dose and tapering of glucocorticoids (GC) in LN remains unknown. We aimed to assess whether a higher prednisone dose results in better 12-month complete renal response (CRR) rates compared with a lower dose, in a contemporary multicentre cohort of LN patients. METHODS: Retrospective and prospective cohort study of patients with new-onset biopsy-proven LN (period 2014-to date). Overall and complete renal response rates at 12 months were compared between patients who started with high (>40 mg/day) vs low-medium (≤40 mg/day) prednisone dose. Multivariable regression and time-to-response analyses were performed, applying inverse probability of treatment weighting (IPTW) to balance baseline covariates and minimize confounding. RESULTS: A total of 162 patients were included; 101 received a low-medium starting prednisone dose (median 30 mg/day) and 61 received a high dose (median 60 mg/day). Cumulative prednisone exposure in the first year was significantly higher in the high-dose group (6.9 g vs 4.0 g; P < 0.001), although cumulative doses equalized by years 2 and 3. The 12-month CRR rates were comparable between the high- and medium-dose groups (65.4% in the low-medium vs 71.2% in the high-dose group, P = 0.55). In multivariable logistic regression with IPTW, a higher initial prednisone dose was not associated with better CRR rate (adjusted OR 1.00; 95% CI: 0.46-2.22). Similarly, time-to-response analyses showed no difference in achieving overall renal response (log-rank P = 0.26). CONCLUSION: Despite significantly increasing GC exposure, a higher starting prednisone dose was not associated with improved renal response rates at 12 months in a contemporary LN cohort.
引用
- Pappa M, Flouda S, Pieta A, et al. Comparable 12-month renal response outcomes with medium- vs high-dose starting prednisone in a real-world study of Lupus Nephritis. Rheumatology (Oxford). 2026. PMID: 41165598. doi:10.1093/rheumatology/keaf574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。